Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 9/20 | 0.56 |
| ▸ | JAK2 | O60674 | 10/20 | 0.56 |
| ▸ | JAK3 | P52333 | 10/20 | 0.56 |
| ▸ | JAK1 | P23458 | 9/20 | 0.56 |
| ▸ | TYK2 | P29597 | 9/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4498049 | 0.81 | JAK2 (0.65) | CHEK1JAK2JAK3JAK1TYK2 | |
| SCHEMBL4501297 | 0.79 | CHEK1 (0.55) | CHEK1JAK2JAK3JAK1TYK2 | |
| SCHEMBL5796180 | 0.78 | MERTK (0.46) | CHEK1JAK2JAK3JAK1TYK2 | |
| SCHEMBL4504684 | 0.77 | CHEK1 (0.54) | CHEK1JAK2JAK3JAK1TYK2 | |
| SCHEMBL13606530 | 0.77 | JAK2 (0.56) | CHEK1JAK2JAK3JAK1TYK2 | |
| SCHEMBL4502294 | 0.76 | JAK2 (0.55) | CHEK1JAK2JAK3JAK1TYK2 | |
| SCHEMBL4502872 | 0.75 | JAK2 (0.56) | CHEK1JAK2JAK3JAK1TYK2 | |
| SCHEMBL4564373 | 0.74 | CHEK1 (0.68) | CHEK1KCNH2 | |
| SCHEMBL4509789 | 0.74 | CHEK1 (0.62) | CHEK1KCNH2 | |
| SCHEMBL13606546 | 0.73 | JAK2 (0.70) | CHEK1JAK2JAK3JAK1TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-7635695-B2 | Antiinflammation agents | AMGEN INC. (US) | 2009-12-22 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-20070155777-A1 | Antiinflammation agents | AMGEN, INC. | 2007-07-05 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
| US-7199119-B2 | Antiinflammation agents | AMGEN INC. (US) | 2007-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155777-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | CHEK1 3814/4885JAK2 1101/4885JAK3 1936/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.